Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis

Matthew F. Cusick, Jane E. Libbey, Luke Oh, Shaun Jordan, Robert S. Fujinami*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Acthar gel is indicated for the treatment of acute exacerbations of multiple sclerosis (MS) in adults. Its effects on immune cells during a relapse are unknown. This study investigated the effects of Acthar in an animal model of relapsing-remitting MS, using SJL/J mice sensitized with myelin peptide. All animal studies were reviewed and approved by the University of Utah Institutional Animal Care and Use Committee and conducted in accordance with the guidelines prepared by the Committee on Care and Use of Laboratory Animals, Institute of Laboratory Animals Resources, National Research Council. Mice injected with Acthar to treat the second attack had a significantly lower mean clinical score during relapse and a significantly reduced cumulative disease burden compared to Placebo gel-treated mice. Furthermore, Acthar treatment ameliorated inflammation/demyelination in the spinal cord and markedly suppressed ex vivo myelin peptide-induced CD4+ T cell proliferation.

Original languageEnglish (US)
Pages (from-to)222-230
Number of pages9
JournalAutoimmunity
Volume48
Issue number4
DOIs
StatePublished - Jun 1 2015

Keywords

  • ACTH
  • Demyelination
  • Experimental autoimmune encephalomyelitis
  • Inflammation
  • T cell

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Acthar gel treatment suppresses acute exacerbations in a murine model of relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this